Bufonis venenum extract loaded novel cholesterol-free liposome for the treatment of hepatocellular carcinoma

Siqi Yang, Jinshuai Lan, Zhe Li, Ming Li, Ya Wu, Liyan Sun, Tong Zhang, Yue DingFrontiers in Pharmacology 2024 · DOI

TL;DR

Researchers have developed a novel, cholesterol-free liposome that uses the natural steroid-like components of toad venom (Bufonis venenum) to stabilize its own delivery structure. This "self-stabilizing" nanocarrier significantly improves the solubility and safety of the extract, achieving anti-tumor efficacy in mice equivalent to the gold-standard drug sorafenib while reducing toxic side effects.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide, often diagnosed at advanced stages where surgical options are limited. While traditional Chinese medicines like Bufonis venenum (BVE)—an extract from toad skin secretions—show potent anti-cancer activity, they are notoriously difficult to use. BVE contains a mix of lipophilic bufadienolides and hydrophilic indolealkylamines that suffer from poor water solubility, rapid clearance from the body, and significant "off-target" toxicity, including heart palpitations and nausea.

Standard drug delivery systems like liposomes usually require cholesterol to keep their membranes stable. However, high cholesterol levels can lead to cardiovascular issues. The authors sought to create a "cholesterol-free" liposome by leveraging the fact that BVE’s own active components are structurally similar to steroids, potentially allowing the drug to serve as its own structural stabilizer.

Methods

The team used a thin-film evaporation technique to create the "Non-Chol-BVE-LP" (Non-Cholesterol-Bufonis Venenum Extract-Liposome).

  • The Innovation: Instead of adding external cholesterol, they used the bufadienolides within the BVE to stabilize the phospholipid bilayer (composed of DSPC and DSPE-mPEG2000). This creates a dual-loading system: lipophilic compounds sit in the membrane "skin," while hydrophilic compounds are trapped in the watery core.
  • Testing: They characterized the particles using Transmission Electron Microscopy (TEM) and Dynamic Light Scattering.
  • Biological Evaluation: They performed in vitro cytotoxicity and apoptosis assays on HepG2 (liver cancer) cells.
  • Animal Models: They used BALB/C mice with HepG2 tumors to track biodistribution (using fluorescent ICG markers) and measured tumor shrinkage over two weeks compared to sorafenib, the standard clinical treatment.

Datasets

As a pharmacology study, this paper does not use computational datasets. Instead, it relies on primary experimental data from:

  • Cell Lines: HepG2 (human liver cancer) and LO2 (normal liver cells).
  • Animal Models: Male Sprague Dawley rats (for blood safety/hemolysis tests) and BALB/C mice (for tumor growth studies).

Key Insights and Ideas

  • Molecular Mimicry: The most elegant finding is that bufadienolides can functionally replace cholesterol in a liposome membrane. This reduces the "inactive" ingredient load and avoids the side effects of supplemental cholesterol.
  • Enhanced Permeability and Retention (EPR): The liposomes (averaging ~81 nm) are small enough to accumulate preferentially in tumor tissues through leaky blood vessels—a process called passive targeting.
  • Improved Bioavailability: The liposomal formulation showed a "sustained-release" profile. While free BVE is released almost entirely within 30 minutes, the liposome version released its payload slowly over 8 hours, maintaining a steadier therapeutic window.
  • Safety First: One of the biggest hurdles for BVE is hemolysis (rupturing red blood cells). The study found that encapsulating BVE in these liposomes kept the hemolysis rate below 5%, making it safe for intravenous injection.

Key Results

  • High Efficiency: The liposomes achieved an encapsulation efficiency of 91.2%.
  • Superior Potency: In cell cultures, the liposome (IC50: 0.17 µg/mL) was more effective at killing cancer cells than the raw extract (IC50: 0.24 µg/mL).
  • Tumor Inhibition: In live mice, the Non-Chol-BVE-LP achieved a 80.42% tumor inhibition rate. This is statistically equivalent to sorafenib (79.75%), the first-line pharmaceutical for HCC.
  • Targeted Accumulation: Fluorescent imaging confirmed that the liposomes stayed in the tumor significantly longer than the free-floating drug, which was cleared rapidly by the liver and kidneys.

Limitations and Future Work

While the results are promising, the authors acknowledge a few areas for further exploration:

  • Specific Mechanisms: While they observed increased apoptosis (programmed cell death), the exact molecular pathways BVE uses to kill HCC cells within this specific nanocarrier need deeper mapping.
  • Long-term Stability: The study tested stability for 30 days; however, clinical applications would require longer-term shelf-life data.
  • Combination Therapy: Future research could investigate whether these liposomes work synergistically with existing chemotherapies or immunotherapies to overcome the drug resistance often seen in HCC patients.

Summary updated

Abstract

The study provided new ideas for the development and clinical application of Bufonis venenum related formulation and offered new drug for the treatment of HCC.
BibTeX
@inproceedings{yang2024bufonis,
  author = {Siqi Yang and Jinshuai Lan and Zhe Li and Ming Li and Ya Wu and Liyan Sun and Tong Zhang and Yue Ding},
  title = {{Bufonis venenum extract loaded novel cholesterol-free liposome for the treatment of hepatocellular carcinoma}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1486742},
}
Figure